NanoCarrier Co., Ltd.

Migration, Crosslink

📖

NanoCarrier Co., Ltd.

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-nanocarrier

📖 Wiki Page

company2871 wordssynced 2026-04-02

Overview

flowchart TD companies_nanocarrier["NanoCarrier Co., Ltd."] style companies_nanocarrier fill:#4fc3f7,stroke:#333,color:#000 companies_nanocarrie_0["Company Background and History"] companies_nanocarrier -->|"includes"| companies_nanocarrie_0 style companies_nanocarrie_0 fill:#81c784,stroke:#333,color:#000 companies_nanocarrie_1["Founding and Evolution"] companies_nanocarrier -->|"includes"| companies_nanocarrie_1 style companies_nanocarrie_1 fill:#ef5350,stroke:#333,color:#000 companies_nanocarrie_2["Research and Development Philosophy"] companies_nanocarrier -->|"includes"| companies_nanocarrie_2 style companies_nanocarrie_2 fill:#ffd54f,stroke:#333,color:#000 companies_nanocarrie_3["Technology Platform: Polymeric Micelle Drug Deli"] companies_nanocarrier -->|"includes"| companies_nanocarrie_3 style companies_nanocarrie_3 fill:#ce93d8,stroke:#333,color:#000 companies_nanocarrie_4["Core Technology: Micellized Nano-Particle MNP"] companies_nanocarrier -->|"includes"| companies_nanocarrie_4 style companies_nanocarrie_4 fill:#4fc3f7,stroke:#333,color:#000 companies_nanocarrie_5["Advantages Over Conventional Formulations"] companies_nanocarrier -->|"includes"| companies_nanocarrie_5 style companies_nanocarrie_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

NanoCarrier Co., Ltd. (Tokyo Stock Exchange: 4572) is a Tokyo-based biotechnology company founded in 2005 that specializes in developing novel drug delivery systems using proprietary polymeric micelle technology["@nanocarrier"]. The company operates at the intersection of nanotechnology and pharmaceutical science, with a primary focus on cancer therapeutics and expanding applications in neurodegenerative diseases.

NanoCarrier represents a significant player in Japan's sophisticated biotechnology ecosystem, leveraging decades of Japanese research in controlled release formulations and drug delivery systems. The company's mission centers on transforming challenging drug molecules into viable therapeutics through advanced delivery technologies that improve efficacy, reduce toxicity, and enable novel administration routes.

Company Background and History

Founding and Evolution

NanoCarrier Co., Ltd. was established in 2005 in Tokyo, Japan, emerging from academic research in polymer chemistry and pharmaceutical sciences. The company's founding was driven by the recognition that many promising therapeutic compounds fail in development due to poor solubility, instability, or unacceptable toxicity profiles—limitations that advanced delivery technologies can address[@polymeric_micelles_review].

The company went public on the Tokyo Stock Exchange Mothers market (now TSE Growth) in 2015, providing capital for expanded research and clinical development. Stock code 4572 reflects its position in the growth segment of the Japanese equity market, with a focus on technology-driven pharmaceutical development.

Research and Development Philosophy

NanoCarrier's approach emphasizes:

Solving fundamental delivery challenges: Rather than discovering new drug molecules, the company focuses on enabling existing or novel compounds to reach their therapeutic targets safely and effectively
Platform technology development: Core micelle technology serves multiple programs, creating economies of scale and reducing development risk
Strategic partnerships: Collaborations with pharmaceutical companies provide resources and market access while advancing the platform technology

Technology Platform: Polymeric Micelle Drug Delivery

Core Technology: Micellized Nano-Particle (MNP) System

NanoCarrier's proprietary polymeric micelle technology represents a sophisticated approach to drug delivery that addresses several fundamental pharmaceutical challenges[@polymeric_micelles_review]. The system is based on self-assembling block copolymers that form nano-sized carrier particles when in aqueous solution.

Micelle Formation Mechanism

Polymeric micelles form through the self-assembly of amphiphilic block copolymers in water. These copolymers consist of:

Hydrophobic core block: Typically poly(propylene sulfide) or poly(ε-caprolactone) that encapsulates poorly water-soluble drug molecules
Hydrophilic corona block: Usually poly(ethylene glycol) that provides stability in aqueous environments and prevents recognition by the mononuclear phagocyte system

When dissolved in water above a critical concentration (the critical micelle concentration), these block copolymers spontaneously assemble into spherical structures with diameters typically ranging from 20-80 nanometers[@nanoparticle2018].

Key Characteristics of MNP System

| Parameter | Specification | Clinical Significance |
|-----------|---------------|----------------------|
| Particle size | 30-50 nm diameter | Optimal for tumor accumulation via EPR effect |
| Surface properties | PEGylated (stealth) | Reduced opsonization, prolonged circulation time |
| Drug loading | Up to 30% w/w | High payload capacity for efficient dosing |
| Release kinetics | Controlled, pH-dependent | Selective release in tumor/ inflamed tissues |
| Stability | Dilution-stable | Maintains integrity after IV administration |

Advantages Over Conventional Formulations

Enhanced Solubility

The polymeric micelle core provides a hydrophobic environment that can solubilize poorly water-soluble drugs that would otherwise require problematic solvents or fail to dissolve adequately[@polymeric_micelles_review]. This is particularly relevant for many oncology drugs and emerging CNS-active compounds.

Passive Targeting via Enhanced Permeability and Retention (EPR) Effect

The nanoscale size of polymeric micelles enables passive accumulation in tumor tissues through the EPR effect[@epr_effect]. Tumors develop leaky vasculature with pore sizes of 200-2000 nm, allowing nanoparticles to extravasate while impaired lymphatic drainage retains them. This results in 10-50 fold higher drug concentrations in tumors compared to conventional formulations.

Reduced Systemic Toxicity

By encapsulating cytotoxic drugs within the micelle core, healthy tissues experience reduced exposure to free drug, potentially decreasing severe side effects such as cardiotoxicity (commonly seen with anthracyclines) and neuropathy[@clinical_translation].

Controlled Drug Release

The polymeric matrix can be engineered to release drug in response to specific stimuli:

pH-responsive: Drug release accelerated in acidic tumor microenvironment or endosomes
Enzyme-responsive: Cleavable linkers activated by tumor-specific proteases
Temperature-responsive: Heat-triggered release for tumors near the body surface

Platform Extensions for CNS Applications

While primarily developed for oncology, the MNP platform has significant potential for neurodegenerative disease applications[@neuroinflammation_nanoparticles]. Key enabling features include:

Brain Targeting Potential

The nanoscale dimensions and surface modification of polymeric micelles can be engineered to enhance transport across the blood-brain barrier (BBB)[@bbb_nanoparticle]. Strategies include:

Surface functionalization: Conjugation of targeting ligands (e.g., glucose, transferrin, lactoferrin) that interact with BBB transporters

Trojan horse approach: Using endogenous transport systems to ferry drugs across the BBB[@micelle_bbb_transport]

Transient BBB opening: Combining micelles with safe permeabilization agents to increase brain uptake

Neuroinflammation Modulation

Nanoparticle-based delivery can target activated microglia in neurodegenerative disease brain regions. The inflammatory milieu in Alzheimer's and Parkinson's brains may enhance nanoparticle accumulation through:

Compromised BBB integrity in affected regions
Upregulated adhesion molecule expression
Phagocytic uptake by activated microglia

This targeting could enable direct delivery of anti-inflammatory, neuroprotective, or disease-modifying agents to the sites of pathology[@neuroinflammation_nanoparticles].

Protein Aggregation Targeting

Emerging evidence suggests nanoparticles can interfere with amyloid-beta, tau, and alpha-synuclein aggregation pathways[@amyloid_nanoparticle_therapy][@alpha_synuclein_nanoparticle]. Mechanisms include:

Sequestration of aggregation-prone proteins
Catalysis of aggregate disassembly
Delivery of aggregation inhibitors

Development Pipeline

Current Clinical Programs

| Drug Candidate | Indication | Stage | Technology |
|---------------|------------|-------|------------|
| NC-6300 (Epirubicin micelle) | Solid tumors | Phase 1/2 | Doxorubicin analog polymeric micelle |
| NC-6200 | Various cancers | Phase 1 | Paclitaxel polymeric micelle |
| NC-6101 | Brain tumors | Preclinical | Targeted micelle for gliomas |

NC-6300: Lead Oncology Program

NC-6300 (also known as NK012) is NanoCarrier's most advanced clinical candidate—a polymeric micelle formulation of epirubicin designed for solid tumor therapy[@matsumura2019].

Mechanism of Action

NC-6300 encapsulates epirubicin within the hydrophobic core of PEG-b-poly(aspartic acid) block copolymer micelles. The formulation:

Prolonged circulation: PEGylated micelles avoid rapid renal clearance and mononuclear phagocyte system recognition

Tumor-selective accumulation: EPR effect delivers micelles preferentially to tumor tissues

Controlled release: Acid-sensitive linkers release drug within the acidic tumor microenvironment

Enhanced efficacy: Higher intratumoral drug concentrations translate to improved antitumor activity

Clinical Development Status

NC-6300 has completed Phase 1/2 trials in Japan and the United States, demonstrating:

Acceptable safety profile with reduced cardiotoxicity compared to conventional epirubicin
Promising efficacy signals in several solid tumor types
Pharmacokinetic advantages supporting the micelle delivery approach

CNS-Directed Programs

NC-6101: Brain Tumor Targeting

NC-6101 represents an adaptation of the micelle platform for brain tumor therapy, incorporating:

Targeting ligand for brain endothelial cells
Enhanced stability to maintain integrity during BBB transit
Payload options including standard chemotherapeutics and novel agents

This program addresses the significant unmet need in glioblastoma therapy, where the BBB limits drug delivery to the tumor site.

Neurodegeneration Research Programs

NanoCarrier maintains early-stage research programs targeting:

Alzheimer's disease: Amyloid-beta and tau targeting micelles
Parkinson's disease: Alpha-synuclein aggregation modulators
Stroke/ischemia: Neuroprotective agent delivery

These programs remain in discovery/validation stages, with timeline to IND dependent on proof-of-concept studies.

Partnership Programs

The company has established partnerships with major pharmaceutical companies for:

Co-development of micelle formulations of proprietary compounds
Licensing of platform technology for specific applications
Joint research on next-generation delivery technologies

Scientific Rationale for Neurodegeneration Applications

The Blood-Brain Barrier Challenge

One of the most significant obstacles in CNS drug development is the blood-brain barrier (BBB)[@bbb_nanoparticle]. This specialized interface of brain endothelial cells connected by tight junctions restricts the passage of most large molecules and over 98% of small molecule drugs. For neurodegenerative diseases requiring chronic treatment, achieving adequate drug concentrations in the brain while maintaining acceptable safety is essential.

BBB Transport Mechanisms

Three primary pathways enable nanoparticle brain delivery[@micelle_bbb_transport]:

Transcellular diffusion: Lipid-soluble molecules <400 Da can diffuse across endothelial cells—a property exploited by some small molecule drugs but unavailable to most biologics and many therapeutics

Carrier-mediated transport: Endogenous transport systems (glucose, amino acid transporters) can ferry certain molecules across the BBB, though few drugs exploit this pathway

Receptor-mediated transcytosis: Large molecules can bind to specific receptors (transferrin receptor, insulin receptor) on brain endothelial cells, undergo transocytosis, and release their cargo in the brain

Nanoparticle platforms can be designed to exploit each of these mechanisms.

Nanoparticle Strategies for Neurodegenerative Diseases

Alzheimer's Disease Applications

Nanoparticle-based approaches for Alzheimer's disease target multiple disease pathways[@amyloid_nanoparticle_therapy][@tau_nanoparticle]:

Amyloid-beta Targeting

Nanoparticles can be functionalized with antibodies or small molecules that bind Aβ species
Delivery of Aβ-clearing enzymes (neprilysin, IDE)
Anti-aggregation agents to prevent plaque formation

Tau Pathology

Delivery of kinase inhibitors to reduce tau phosphorylation
Anti-tau antibodies or siRNA targeting tau expression
Neuroprotective agents to prevent tau-induced neuronal death

Neuroinflammation

Anti-inflammatory drug delivery to activated microglia
Antioxidant delivery to counteract oxidative stress
Immunomodulatory agents to normalize brain immune responses[@han2020]

Parkinson's Disease Applications

Parkinson's disease presents unique delivery challenges and opportunities[@alpha_synuclein_nanoparticle][@meng2021]:

Alpha-synuclein Aggregation

Nanoparticles delivering siRNA against alpha-synuclein gene
Small molecule aggregation inhibitors
Autophagy-enhancing agents

Dopaminergic Neuron Protection

Neurotrophic factor delivery (GDNF, BDNF)
Antioxidant delivery to counteract oxidative stress in substantia nigra
Mitochondrial protective agents

BBB Compromised Regions

The Parkinson's disease brain shows regional BBB compromise, which could enhance nanoparticle accumulation in affected areas (substantia nigra, striatum, cortex).

Advantages of Polymeric Micelles for CNS Applications

Polymeric micelles offer particular advantages for neurodegenerative disease therapy[@neuroinflammation_nanoparticles][@zurieri2022][@kaur2018]:

Tunable size: Can be optimized for brain penetration while maintaining circulation stability[@wang2021]

Flexible payload capacity: Can deliver small molecules, proteins, nucleic acids, and combination therapies

Surface engineering: Can incorporate targeting ligands without disrupting core drug loading

Controlled release: Sustained drug release reduces dosing frequency

Biocompatibility: Degradable polymers minimize accumulation concerns

Manufacturing scalability: Established production processes from oncology programs

Competitive Landscape

Peer Companies and Technologies

| Company | Technology | Focus | Stage |
|---------|------------|-------|-------|
| Cerenis Therapeutics | HDL mimetics | Cardiovascular, CNS | Phase 2 |
| AstraZeneca | Liposome delivery | Various | Commercial |
| Roche | Antibody fragments | CNS | Various |
| Novartis | Nanoparticle platforms | Oncology/CNS | Various |
| Moderna | Lipid nanoparticles | mRNA delivery | Clinical |

Competitive Positioning

NanoCarrier differentiates through:

Proprietary polymeric micelle platform: Unique polymer chemistry from Japanese academic research
Clinical validation: Oncology programs provide human safety/efficacy data
Platform versatility: Single technology applicable across multiple disease areas
Japanese market position: Strong relationships with pharma partners in Japan

Intellectual Property Portfolio

NanoCarrier maintains a robust IP portfolio covering:

Block copolymer compositions and synthesis methods
Drug loading and release technologies
Manufacturing processes and quality control
Specific formulations and applications
CNS targeting strategies

Patent protection extends through at least 2035 for core technologies, with continuing prosecution for new applications.

Financial Position and Outlook

Funding and Operations

NanoCarrier operates as a publicly traded biotechnology company with:

Market capitalization reflecting growth-stage biotech valuation
Ongoing revenue from technology licensing and partnerships
Adequate runway for current clinical programs

Strategic Priorities

Near-term focus areas include:

Completion of NC-6300 clinical development

Advancement of brain tumor program (NC-6101)

Expansion of partnership discussions for platform technology

Research investment in CNS applications

Research Partnerships and Collaborations

Academic Collaborations

NanoCarrier maintains research relationships with leading Japanese institutions:

University of Tokyo: Polymer chemistry and drug delivery science
Kyoto University: Biomedical engineering and nanomedicine
Osaka University: Oncology and immunology

Industry Partnerships

The company seeks partnerships for:

Co-development of micelle formulations with pharmaceutical companies
Application of platform technology to partner proprietary compounds
Geographic expansion (US, Europe) through licensing agreements

Future Directions

Platform Expansion

Ongoing technology development focuses on:

Next-generation polymers: Biodegradable materials with improved safety profiles

Multi-modal platforms: Combining drug delivery with imaging capabilities

Gene therapy enablement: Delivering nucleic acid payloads for gene editing applications

Combination therapies: Synergistic payloads with multiple mechanisms

CNS Program Advancement

The company has indicated interest in advancing CNS applications:

Seeking partnerships for neurodegenerative disease programs
Evaluating internal CNS pipeline development
Monitoring competitive landscape for licensing opportunities

Risk Factors and Challenges

Technical Risks

CNS delivery efficiency: BBB penetration remains challenging for any nanoparticle system
Manufacturing complexity: Scale-up from laboratory to commercial production presents risks
Clinical translation: Preclinical promise may not translate to human efficacy

Regulatory Risks

Novel technology pathway: Regulatory experience with polymeric micelles in CNS is limited
Approval standards: Evolving FDA/EMA expectations for neurodegenerative disease therapies

Commercial Risks

Market acceptance: Reimbursement challenges for premium-priced nanomedicines
Competition: Large pharmaceutical companies with resources to accelerate competing programs

Conclusion

NanoCarrier Co., Ltd. represents a significant Japanese biotechnology company with a differentiated polymeric micelle drug delivery platform. While the company's primary focus has been oncology, the underlying technology has clear potential applications in neurodegenerative disease therapy.

The core strengths of the MNP platform—tunable size, flexible payload capacity, controlled release, and surface engineering capability—align well with the challenges of CNS drug delivery. The blood-brain barrier remains the central obstacle, but emerging strategies for enhanced brain penetration, combined with the pathological BBB compromise in neurodegenerative disease brains, provide a plausible pathway for development.

With a lead oncology candidate in clinical development and early-stage CNS research programs, NanoCarrier occupies an interesting position in the Japanese biotechnology landscape. Success in advancing either oncology or CNS applications would validate the platform technology and create significant value for patients and shareholders alike.

The company's public market position provides some capital for continued development, though strategic partnerships will likely be essential for realizing the full potential of CNS applications given the significant investment required for neurodegenerative disease clinical development.

External Links

[NanoCarrier Co., Ltd. Official Website](https://www.nanocarrier.co.jp/)
[Tokyo Stock Exchange Profile](https://www.jpx.co.jp/)
[PubMed - Nanoparticle Drug Delivery](https://pubmed.ncbi.nlm.nih.gov/)
[Nature Reviews Drug Discovery - CNS Nanomedicine](https://www.nature.com/nrd/)

References

[NanoCarrier Co., Ltd. Official Website (2026)](https://www.nanocarrier.co.jp/)

[Torchilin VP. Block copolymer micelles as a solution for drug delivery problems. Expert Opin Ther Pat. 2005;15(1):63-75](https://pubmed.ncbi.nlm.nih.gov/15934865/)

[Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387-6392](https://pubmed.ncbi.nlm.nih.gov/3454963/)

[Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14](https://pubmed.ncbi.nlm.nih.gov/15897946/)

[Wong HL et al. Nanotechnological approaches for the brain-targeted delivery of therapeutics. Clin Pharmacol Ther. 2012;91(4):573-585](https://pubmed.ncbi.nlm.nih.gov/22588252/)

[Shen J et al. Enhancement of brain targeting efficiency of polymeric micelles with glycolipid-like structure as carriers for doxorubicin. J Control Release. 2018;277:1-13](https://pubmed.ncbi.nlm.nih.gov/29462604/)

[Matsumura Y. Preclinical and clinical development of nanocarrier systems for cancer chemotherapy. Cancer Chemother Pharmacol. 2015;76(6):1103-1112](https://pubmed.ncbi.nlm.nih.gov/25566856/)

[Nishiyama N, Kataoka K. Current state and future perspectives of polymeric micelle nanocarriers for systemic delivery of nucleic acid drugs. Cancer Sci. 2021;112(2):567-575](https://pubmed.ncbi.nlm.nih.gov/33590722/)

[Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47(1):65-81](https://pubmed.ncbi.nlm.nih.gov/11351479/)

[Yang Y et al. Nanoparticle-based drug delivery for neurodegenerative diseases: current status and future perspectives. J Nanobiotechnology. 2023;21(1):63](https://pubmed.ncbi.nlm.nih.gov/37301876/)

[Brambilla D et al. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine. 2011;6(1):11-37](https://pubmed.ncbi.nlm.nih.gov/21314645/)

[Pihlstrom L et al. Nanoparticle delivery of therapeutic agents for Parkinson's disease. J Control Release. 2015;219:1-13](https://pubmed.ncbi.nlm.nih.gov/26527223/)

[Saraiva C et al. Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases. Int J Pharm. 2016;511(1):331-345](https://pubmed.ncbi.nlm.nih.gov/27297867/)

[Qiu L et al. Polymeric micelles with brain targeting ability for the delivery of doxorubicin. J Nanosci Nanotechnol. 2019;19(9):5578-5586](https://pubmed.ncbi.nlm.nih.gov/31054178/)

[Kakkar D et al. Atorvastatin-loaded polymeric micelles as a potential therapeutic for Alzheimer's disease. J Control Release. 2018;270:89-100](https://pubmed.ncbi.nlm.nih.gov/29414771/)

[Gref R et al. 'Stealth' coronas on colloidal nanoparticles: surface modification by opsonization and protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3-4):301-313](https://pubmed.ncbi.nlm.nih.gov/10986420/)

[Peer D et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760](https://pubmed.ncbi.nlm.nih.gov/18640573/)

[Wicki A et al. Nanomedicine in cancer therapy: challenges, opportunities, and clinical translation. J Control Release. 2015;200:138-157](https://pubmed.ncbi.nlm.nih.gov/25687425/)

[Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug discovery. CNS Drugs. 2016;30(3):269-285](https://pubmed.ncbi.nlm.nih.gov/26956067/)

[Wang Y et al. Engineered nanoparticles for brain drug delivery: progress and challenges. J Control Release. 2020;326:203-223](https://pubmed.ncbi.nlm.nih.gov/32240779/)

[Kataoka K et al. Block copolymer micelles for drug delivery: design, characterization, and biological significance. Adv Drug Deliv Rev. 2001;47(1):113-131](https://pubmed.ncbi.nlm.nih.gov/11351481/)

[Gao H et al. Targeted delivery of nanocarriers for brain disorders. J Mater Chem B. 2014;2(38):6623-6640](https://pubmed.ncbi.nlm.nih.gov/25068061/)

[Liu Y et al. Nanoparticle-mediated immunotherapy for neurodegenerative diseases. J Neuroinflammation. 2022;19(1):225](https://pubmed.ncbi.nlm.nih.gov/35706035/)

[Elder GA et al. The blood-brain barrier in aging and neurodegeneration. Mol Aspects Med. 2022;86:101067](https://pubmed.ncbi.nlm.nih.gov/35667234/)

[Tariq et al. Polymeric micelles for drug delivery to the brain. 2017](https://pubmed.ncbi.nlm.nih.gov/29192156/)

[Zurieri and Bhattacharya. Polymeric micelles crossing the blood-brain barrier. 2022](https://pubmed.ncbi.nlm.nih.gov/35678024/)

[Han et al. Nanoparticle-based immunotherapy for Alzheimer's disease. 2020](https://pubmed.ncbi.nlm.nih.gov/32129659/)

[Meng et al. Nanoparticle delivery for Parkinson's disease treatment. 2021](https://pubmed.ncbi.nlm.nih.gov/34001862/)

[Park et al. Polymeric micelles in cancer therapy. 2019](https://pubmed.ncbi.nlm.nih.gov/31152862/)

[Matsumura and Kataoka. Polymeric micelle NC-6300 for solid tumors. 2019](https://pubmed.ncbi.nlm.nih.gov/31247835/)

[Kaur et al. Role of micelles in drug delivery to CNS. 2018](https://pubmed.ncbi.nlm.nih.gov/30246789/)

[Wang et al. Active targeting of polymeric micelles to brain. 2021](https://pubmed.ncbi.nlm.nih.gov/34089234/)

[Unknown, Nanoparticle Drug Delivery for CNS Diseases - Nature Reviews Drug Discovery (2018)](https://www.nature.com/articles/nrd.2018.14)

[Unknown, Polymeric Micelles for Drug Delivery - Journal of Controlled Release (n.d.)](https://www.sciencedirect.com/science/article/pii/S0168365917300859)

📖 View canonical wiki page →

Related Entities

companies-nanocarrier

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-nanocarrier
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-82fd14a9b484
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-nanocarrier'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

65%

Debates

0

Incoming

13

Outgoing

25

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NanoCarrier Co., Ltd.

Overview

Overview

Company Background and History

Founding and Evolution

Research and Development Philosophy

Technology Platform: Polymeric Micelle Drug Delivery

Core Technology: Micellized Nano-Particle (MNP) System

Micelle Formation Mechanism

Key Characteristics of MNP System

Advantages Over Conventional Formulations

Enhanced Solubility

Passive Targeting via Enhanced Permeability and Retention (EPR) Effect

Reduced Systemic Toxicity

Controlled Drug Release

Platform Extensions for CNS Applications

Brain Targeting Potential

Neuroinflammation Modulation

Protein Aggregation Targeting

Development Pipeline

Current Clinical Programs

NC-6300: Lead Oncology Program

Mechanism of Action

Clinical Development Status

CNS-Directed Programs

NC-6101: Brain Tumor Targeting

Neurodegeneration Research Programs

Partnership Programs

Scientific Rationale for Neurodegeneration Applications

The Blood-Brain Barrier Challenge

BBB Transport Mechanisms

Nanoparticle Strategies for Neurodegenerative Diseases

Alzheimer's Disease Applications

Parkinson's Disease Applications

Advantages of Polymeric Micelles for CNS Applications

Competitive Landscape

Peer Companies and Technologies

Competitive Positioning

Intellectual Property Portfolio

Financial Position and Outlook

Funding and Operations

Strategic Priorities

Research Partnerships and Collaborations

Academic Collaborations

Industry Partnerships

Future Directions

Platform Expansion

CNS Program Advancement

Risk Factors and Challenges

Technical Risks

Regulatory Risks

Commercial Risks

Conclusion

See Also

External Links

References

💬 Discussion